IRCCS San Camillo Hospital, Venice, Italy
Email verificata su
Citata da
Citata da
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind…
JF Howard Jr, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, ...
The Lancet Neurology 16 (12), 976-986, 2017
Regulation of ER-mitochondria contacts by Parkin via Mfn2
V Basso, E Marchesan, C Peggion, J Chakraborty, S Von Stockum, ...
Pharmacological research 138, 43-56, 2018
Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS
E Tasca, V Pegoraro, A Merico, C Angelini
Clin Neuropathol 35 (1), 22-30, 2016
Micro-RNAs in ALS muscle: Differences in gender, age at onset and disease duration
V Pegoraro, A Merico, C Angelini
Journal of the neurological sciences 380, 58-63, 2017
Hearing impairment in MELAS: new prospective in clinical use of microRNA, a systematic review
A Di Stadio, V Pegoraro, L Giaretta, L Dipietro, R Marozzo, C Angelini
Orphanet journal of rare diseases 13 (1), 1-9, 2018
Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1
C Fritegotto, C Ferrati, V Pegoraro, C Angelini
Neurological Sciences 38 (4), 619-625, 2017
The MTHFR C677T polymorphism modifies age at onset in Parkinson’s disease
A Vallelunga, V Pegoraro, M Pilleri, R Biundo, A De Iuliis, M Marchetti, ...
Neurological Sciences 35 (1), 73-77, 2014
Danon disease: Review of natural history and recent advances
G Cenacchi, V Papa, V Pegoraro, R Marozzo, M Fanin, C Angelini
Neuropathology and applied neurobiology 46 (4), 303-322, 2020
MyomiRNAs dysregulation in ALS rehabilitation
V Pegoraro, A Merico, C Angelini
Brain sciences 9 (1), 8, 2019
Update on polyglucosan storage diseases
G Cenacchi, V Papa, R Costa, V Pegoraro, R Marozzo, M Fanin, ...
Virchows Archiv 475 (6), 671-686, 2019
MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients
V Pegoraro, R Marozzo, C Angelini
Clinical neuropathology 39 (3), 105, 2020
Current and emerging therapies in Becker muscular dystrophy (BMD)
C Angelini, R Marozzo, V Pegoraro
Acta Myologica 38 (3), 172, 2019
MiRNAs as biomarkers of phenotype in neutral lipid storage disease with myopathy
V Pegoraro, S Missaglia, R Marozzo, D Tavian, C Angelini
Muscle & nerve 61 (2), 253-257, 2020
Correlation between ETFDH mutations and dysregulation of serum myomiRs in MADD patients
S Missaglia, V Pegoraro, R Marozzo, D Tavian, C Angelini
European Journal of Translational Myology 30 (1), 2020
A new family with transportinopathy: increased clinical heterogeneity
C Angelini, R Marozzo, E Pinzan, V Pegoraro, MJ Molnar, A Torella, ...
Therapeutic advances in neurological disorders 12, 1756286419850433, 2019
Circulating miR-206 as a Biomarker for Patients Affected by Severe Limb Girdle Muscle Dystrophies
V Pegoraro, C Angelini
Genes 12 (1), 85, 2021
MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy
V Pegoraro, P Cudia, A Baba, C Angelini
Neurological Sciences 41 (10), 2953-2960, 2020
MiRNAs, Myostatin, and Muscle MRI Imaging as Biomarkers of Clinical Features in Becker Muscular Dystrophy
R Marozzo, V Pegoraro, C Angelini
Diagnostics 10 (9), 713, 2020
The clinical and molecular spectrum of autosomal dominant limb-girdle muscular dystrophies focusing on transportinopathy
C Angelini, V Pegoraro, G Cenacchi
Expert Opinion on Orphan Drugs 7 (5), 223-232, 2019
Morphological study of TNPO3 and SRSF1 interaction during myogenesis by combining confocal, structured illumination and electron microscopy analysis
R Costa, MT Rodia, N Zini, V Pegoraro, R Marozzo, C Capanni, ...
Molecular and Cellular Biochemistry 476 (4), 1797-1811, 2021
Il sistema al momento non pu eseguire l'operazione. Riprova pi tardi.
Articoli 1–20